Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
US Market
Holding CRNX?
Track your performance easily

Crinetics Pharmaceuticals (CRNX) Ownership - Who Owns Crinetics Pharmaceuticals?

476 Followers

Crinetics Pharmaceuticals (CRNX) Ownership Overview

7.41%27.35%6.99%13.98%44.26%
6.99% Other Institutional Investors
13.98% ETFs
44.26% Public Companies and
Individual Investors
The ownership structure of Crinetics Pharmaceuticals (CRNX) stock is a mix of institutional, retail, and individual investors. Approximately 48.33% of the company’s stock is owned by Institutional Investors, 7.41% is owned by Insiders, and 44.26% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 25, 2024
Dana Pizzuti
Chief Med And Dev Officer
xxxxxxxxxxxxx
$434435
Apr 02, 2024
xxxxxxxxxxxxx
$811650
Mar 26, 2024
xxxxxxxxxxxxx
$1433675
Mar 22, 2024
Dana Pizzuti
Chief Med And Dev Officer
xxxxxxxxxxxxx
$664763

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
6,112,173Institution6.79%370,947,779
5,776,769Institution6.42%350,592,111
3,727,952Insider5.60%226,249,407
4,154,887Institution4.61%252,160,092
3,448,845Institution3.83%209,310,403
1,605,847Institution1.78%97,458,854
1,476,203Institution1.64%89,590,760
1,385,580Institution1.54%84,090,850
1,225,712Institution1.36%74,388,461
1,159,290Insider1.29%70,357,310

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,448,845Institution3.83%209,310,403
1,605,847Institution1.78%97,458,854
1,385,580Institution1.54%84,090,850
1,053,750Institution1.17%63,952,088
1,036,501Institution1.15%62,905,246
1,006,177Institution1.12%61,064,882
983,316Institution1.09%59,677,448
960,171Institution1.07%58,272,778
928,441Institution1.03%56,347,084
887,006Institution0.99%53,832,394

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,387,422Institution2.65%144,892,641
2,402,086Institution2.67%122,746,595
1,098,864Institution1.22%65,723,056
1,196,959Institution1.33%61,164,605
952,975Institution1.06%48,697,023
789,082Institution0.88%47,889,387
595,767Institution0.66%36,157,099
525,209Institution0.58%26,838,180
434,963Institution0.48%26,015,137
356,798Institution0.40%18,232,378

FAQ

Who Owns Crinetics Pharmaceuticals (CRNX)?
According to the latest TipRanks data, approximately 6.99% of the company's stock is held by institutional investors, 7.41% is held by insiders, and 44.26% is held by retail investors.
    What percentage of Crinetics Pharmaceuticals (CRNX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 6.99% of Crinetics Pharmaceuticals (CRNX) stock is held by institutional investors.
      What percentage of Crinetics Pharmaceuticals (CRNX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 44.26% of Crinetics Pharmaceuticals (CRNX) stock is held by retail investors.
        Who owns the most shares of Crinetics Pharmaceuticals (CRNX)?
        Richard Driehaus owns the most shares of Crinetics Pharmaceuticals (CRNX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis